HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Donald L. Morton Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tafra, L. Articles by Morton, D. L. Search for Related Content PubMed PubMed Citation Articles by Tafra, L. Articles by Morton, D. L.

J Thorac Cardiovasc Surg 1995;110:119-129
© 1995 Mosby, Inc.

GENERAL THORACIC SURGERY

Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax

Santa, Monica, Calif.

Supported by grants CA 12582 and CA 29605 from the National Cancer Institute and by the Joyce and Ben Eisenberg Foundation, Los Angeles, Calif.

Address for reprints: Donald L. Morton, MD, John Wayne Cancer Institute, 2200 Santa Monica Blvd., Santa Monica, CA 90404.

Abstract

Although melanoma that metastasizes to distant sites is generally associated with a median survival of only 6 to 8 months, certain metastatic sites including the lung may carry a better prognosis than others. Surgical therapy for pulmonary metastases remains controversial because of the variable survival rates reported for previous small series. To determine the prognosis and optimal management of patients with melanoma with pulmonary metastases, we reviewed our 22-year melanoma database of over 6100 patients. Of 984 patients with metastatic melanoma involving the lung or thorax, 106 underwent resection by posterior lateral thoracotomy or median sternotomy. There were no operative deaths, and the median follow-up period for surgical patients was 55 months. The remaining 878 patients were treated without operation with immunotherapy, chemotherapy, radiation therapy, or a combination. In both treatment groups the male/female ratio was approximately 2:1. The primary lesion's Clark level of invasion and Breslow thickness and the patient's age at diagnosis of metastatic disease were not significantly different between the two groups. The 1-year, 3-year, and 5-year survival rates for surgical patients were 77%, 37%, and 27%, respectively, compared with 32%, 7%, and 3% for nonsurgical patients; these differences were highly significant (p = 0.0001). The highest 5-year survival rate (39%) occurred in those patients with a single metastatic lesion. Sixty-three percent of the surgical patients received some form of immunotherapy, compared with 34% of the nonsurgical patients. Multivariate analysis showed that resection and immunotherapy with a melanoma cell vaccine were both independent predictors of survival (p < 0.0001). These results indicate that the prognosis associated with metastatic melanoma may be less dismal than previously thought when distant metastases involve thoracic sites. We believe that surgical resection is the treatment of choice for patients with melanoma with pulmonary metastases; when combined with immunotherapy, this regimen offers the best chance for long-term survival. (J THORACCARDIOVASCSURG1995;110:119-29)

This article has been cited by other articles:

				M. K. Gould, J. Fletcher, M. D. Iannettoni, W. R. Lynch, D. E. Midthun, D. P. Naidich, and D. E. Ost Evaluation of Patients With Pulmonary Nodules: When Is It Lung Cancer?: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 108S - 130S. [Abstract] [Full Text] [PDF]

				R. P. Petersen, S. I. Hanish, J. C. Haney, C. C. Miller III, W. R. Burfeind Jr, D. S. Tyler, H. F. Seigler, W. Wolfe, T. A. D'Amico, and D. H. Harpole Jr Improved survival with pulmonary metastasectomy: An analysis of 1720 patients with pulmonary metastatic melanoma J. Thorac. Cardiovasc. Surg., January 1, 2007; 133(1): 104 - 110. [Abstract] [Full Text] [PDF]

				A. M. Parsons, F. C. Detterbeck, and L. A. Parker Accuracy of Helical CT in the Detection of Pulmonary Metastases: Is Intraoperative Palpation Still Necessary? Ann. Thorac. Surg., December 1, 2004; 78(6): 1910 - 1918. [Abstract] [Full Text] [PDF]

				R. Essner, J. H. Lee, L. A. Wanek, H. Itakura, and D. L. Morton Contemporary Surgical Treatment of Advanced-Stage Melanoma Arch Surg, September 1, 2004; 139(9): 961 - 967. [Abstract] [Full Text] [PDF]

				M. B. Faries, R. J. Bleicher, X. Ye, R. Essner, and D. L. Morton Lymphatic Mapping and Sentinel Lymphadenectomy for Primary and Metastatic Pulmonary Malignant Neoplasms Arch Surg, August 1, 2004; 139(8): 870 - 877. [Abstract] [Full Text] [PDF]

				H. Tsao, M. Feldman, J. E. Fullerton, A. J. Sober, D. Rosenthal, and W. Goggins Early Detection of Asymptomatic Pulmonary Melanoma Metastases by Routine Chest Radiographs Is Not Associated With Improved Survival Arch Dermatol, January 1, 2004; 140(1): 67 - 70. [Abstract] [Full Text] [PDF]

				M. H. Chung, R. K. Gupta, E. Hsueh, R. Essner, W. Ye, R. Yee, and D. L. Morton Humoral Immune Response to a Therapeutic Polyvalent Cancer Vaccine After Complete Resection of Thick Primary Melanoma and Sentinel Lymphadenectomy J. Clin. Oncol., January 15, 2003; 21(2): 313 - 319. [Abstract] [Full Text] [PDF]

				D. M. Rose, R. Essner, T. M. D. Hughes, P. C. Y. Tang, A. Bilchik, L. A. Wanek, J. F. Thompson, and D. L. Morton Surgical Resection for Metastatic Melanoma to the Liver: The John Wayne Cancer Institute and Sydney Melanoma Unit Experience Arch Surg, August 1, 2001; 136(8): 950 - 955. [Abstract] [Full Text] [PDF]

				L. E. Spitler, M. L. Grossbard, M. S. Ernstoff, G. Silver, M. Jacobs, F. A. Hayes, and S. J. Soong Adjuvant Therapy of Stage III and IV Malignant Melanoma Using Granulocyte-Macrophage Colony-Stimulating Factor J. Clin. Oncol., April 1, 2000; 18(8): 1614 - 1621. [Abstract] [Full Text] [PDF]

				J. B. Zwischenberger and S. K. Alpard Pulmonary metastasectomy Ann. Thorac. Surg., July 1, 1999; 68(1): 287 - 288. [Full Text] [PDF]